The U.S. Food and Drug Administration (FDA) notified GlaxoSmithKline that the post-marketing trial of Avandia (rosiglitazone) is on “partial clinical hold,” meaning no new patients can be enrolled…
Reader Survey
Please share your feedback! We’re interested to learn more about your experience with American Nurse Journal.